ClinicalTrials.gg

TargetBeta

FAP

fibroblast activation protein alpha · also DPPIV · DASH family

10 programs in company-led studies act on FAP, from 9 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Lutetium-177Novartisphase 32420 runningERBB2the company's pipeline
Gallium-68Philogenphase 3179 runningERBB2the company's pipeline
Fluorine F 18 FAPI-74ruleSOFIEphase 332 running–NCIt
Fluorine F 18 FPyQCPruleBraccophase 211 running–NCIt
HRS-6768Jiangsu HengRui Medicinephase 211 running–the company's pipeline
Anti-FAP Antibody-drug Conjugate OMTX705ruleOncomatryx Biopharma S.L.phase 122 running–NCIt
Gallium Ga 68 NNS309Novartisphase 122 running–the company's pipeline
Actinium Ac 225 RTX-2358ruleRatio Therapeuticsphase 111 running–NCIt
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 111 running–NCIt
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 111 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.